Creative Medical Technology Holdings Inc Cash Flow Conversion Efficiency
Creative Medical Technology Holdings Inc cash flow conversion efficiency. Based on the latest financial reports, Creative Medical Technology Holdings Inc (CELZ) has a cash flow conversion efficiency ratio of -0.170x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.47 Million) by net assets ($8.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Creative Medical Technology Holdings Inc (2006–2025)
Cash flow conversion efficiency of Creative Medical Technology Holdings Inc from 2006 to 2025. This chart illustrates how Creative Medical Technology Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CELZ stock price for real-time trading data and today's change.
Creative Medical Technology Holdings Inc Cash Flow Conversion Ratio Explained
Creative Medical Technology Holdings Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Creative Medical Technology Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Creative Medical Technology Holdings Inc ranked by their cash flow conversion efficiency. Also see Creative Medical Technology Holdings Inc (CELZ) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bri-Chem Corp.
TO:BRY
|
0.008x |
|
Good Shroom Co Inc
V:MUSH
|
-0.642x |
|
Power Line Engineering Public Company Limited
BK:PLE
|
0.243x |
|
Odyssean Investment Trust PLC
LSE:OIT
|
0.000x |
|
Sunshine Biopharma Inc
NASDAQ:SBFM
|
-0.033x |
|
Trinitan Metals and Minerals
JK:PURE
|
0.047x |
|
ARGO GOLD INC.
F:P3U
|
0.038x |
|
Birlik Mensucat Ticaret ve Sanayi Isletmesi AS
IS:BRMEN
|
25.838x |
Annual Cash Flow Conversion Efficiency for Creative Medical Technology Holdings Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of Creative Medical Technology Holdings Inc from 2006 to 2025. Review Creative Medical Technology Holdings Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.52 Million | $-5.86 Million | -0.778x | +6.90% |
| 2024-12-31 | $6.34 Million | $-5.30 Million | -0.836x | -7.71% |
| 2023-12-31 | $10.34 Million | $-8.03 Million | -0.776x | -57.92% |
| 2022-12-31 | $15.86 Million | $-7.80 Million | -0.491x | -126.63% |
| 2021-12-31 | $10.22 Million | $-2.22 Million | -0.217x | -2086.29% |
| 2020-12-31 | $-39.80 Million | $-434.56K | 0.011x | -92.74% |
| 2019-12-31 | $-8.07 Million | $-1.21 Million | 0.150x | -42.95% |
| 2018-12-31 | $-3.99 Million | $-1.05 Million | 0.263x | -33.79% |
| 2017-12-31 | $-2.24 Million | $-889.62K | 0.398x | -85.90% |
| 2016-12-31 | $-157.79K | $-445.23K | 2.822x | +3443.05% |
| 2015-12-31 | $-183.80K | $-14.64K | 0.080x | -29.63% |
| 2014-12-31 | $-153.04K | $-17.32K | 0.113x | -38.23% |
| 2013-12-31 | $-125.03K | $-22.91K | 0.183x | +6.76% |
| 2012-12-31 | $-97.75K | $-16.77K | 0.172x | -11.29% |
| 2011-12-31 | $-72.16K | $-13.96K | 0.193x | -31.88% |
| 2010-12-31 | $-48.11K | $-13.66K | 0.284x | -71.50% |
| 2009-12-31 | $-30.85K | $-30.74K | 0.996x | +101.32% |
| 2008-12-31 | $757.00 | $-57.16K | -75.514x | -15375.15% |
| 2007-12-31 | $26.35K | $-12.86K | -0.488x | -995.05% |
| 2006-12-31 | $20.89K | $1.14K | 0.055x | -- |
About Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DD… Read more